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Summary We have compared the levels of phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activities and the
distribution of their isoenzymes in normal colon, liver and lung tissues, and in colon, liver and lung adenocarcinoma, lung squamous cell
carcinoma and lung carcinoid. All tumours presented higher phosphoglycerate mutase and enolase activities and lower 2,3-
bisphosphoglycerate phosphatase activity than the normal tissues. No changes were observed in the phosphoglycerate mutase isoenzyme
patterns analysed by cellulose acetate electrophoresis. All specimens contained mainly type BB isoenzyme, traces of type MB isoenzyme and
no type MM isoenzyme. However, the tumours had decreased levels of 2,3-bisphosphoglycerate mutase and 2,3-bisphosphoglycerate
mutase-phosphoglycerate mutase hybrid enzyme. Determined by agarose gel electrophoresis, aa-enolase wasthe isoenzyme predominant in
normal lung, colon and livertissue, although ay- andyy-enolase were also present in all tissues. In colon, liver and non-endocrine lung tumours,
the proportions of ay- and yy-enolase decreased. In contrast, in carcinoid tumours of the lung, the proportions of these isoenzymes increased.
Keywords: 2,3-bisphosphoglycerate mutase; 2,3-bisphosphoglycerate phosphatase; enolase; phosphoglycerate mutase; isoenzyme; lung,
colon and liver adenocarcinoma; lung squamous cell carcinoma; lung carcinoid
Phosphoglycerate mutase (D-phosphoglycerate 2,3-phosphomu-
tase, EC 5.4.2.1, PGM) and enolase (2-phospho-D-glycerate
hydrolyase, EC 4.2.1.11) are glycolytic enzymes that catalyse
consecutive reversible reactions connecting the two ATP-gener-
ating reactions in the glycolytic pathway. PGM catalyses the
conversion of 3-phosphoglycerate, product ofthe first ATP-gener-
ating reaction, into 2-phosphoglycerate in the presence of the co-
factor 2,3-bisphosphoglycerate. Enolase catalyses the conversion
of 2-phosphoglycerate into phosphoenolpyruvate, substrate of the
second ATP-generating reaction. In addition to the main mutase
activity, PGM possesses collateral 2,3-bisphosphoglycerate
synthase or 2,3-bisphosphoglycerate mutase activity (BPGM: 1,3-
bisphosphoglycerate + 3-phosphoglycerate -> 3-phosphoglycerate
+ 2,3-bisphosphoglycerate) and 2,3-bisphosphoglycerate phos-
phatase activity (BPGP: 2,3-bisphosphoglycerate -- 3-phospho-
glycerate + Pi), which is stimulated by 2-phosphoglycolate (for
reviews, see Fothergill-Gilmore and Watson, 1989; Wold, 1971).
In mammalian tissues, there are three isoenzymes ofPGM, which
result from the homodimeric and the heterodimeric combinations of
two different subunits coded by separate genes and designated M
(muscle) and B (brain). In early fetal life, type BB-PGM is the only
form present. During myogenesis, the isoenzyme phenotype under-
goes transition, type BB-PGM being replaced by the MM-form,
through the MB isoenzyme. In skeletal muscle, there is an almost
complete transition from the BB- to the MM-PGM, but in heart
muscle complete transition does not occur (Omenn and Cheung,
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1974; Omenn and Hermodson, 1975; Adamson, 1976; Edwards and
Hopkinson, 1977; Mezquita and Carreras, 1981; Mezquita et al,
1981). During sperm cell differentiation, a switch from type BB-
PGM to typeMM-PGM also occurs (Fundele etal, 1987).Therefore,
in adult mammals, mature sperm cells and skeletal muscle contain
almostexclusively type MM-PGM, whereas type BB-PGM is found
in most other tissues. Only in heart are the three PGM isoenzymes
present in substantial amounts (Omenn and Cheung, 1974; Omenn
and Hermodson, 1975; Rosa et al, 1975; Adamson, 1976; Edwards
and Hopkinson, 1977; Mezquita and Carreras, 1981; Carreras et al,
1981; Mezquita etal, 1981; Bartrons andCarreras, 1982; Prehu et al,
1984; Pons et al, 1985a,b; Fundele et al, 1987).
In addition to PGM isoenzymes, in mammalian tissues there are
three other enzyme proteins that have PGM-, BPGM- and 2-phos-
phoglycolate-stimulated BPGPactivities,with aPGM-BPGP and a
PGM-BPGM activity ratios lower than those ofPGM isoenzymes.
One of these enzymes is the 2,3-bisphosphoglycerate synthase-
phosphatase or 2,3-bisphosphoglycerate mutase (EC 5.4.2.4),
which is a homodimer of a subunit that possesses great homology
with PGM subunits (Sasaki et al, 1975; Kappel and Hass, 1976;
Sasaki et al, 1976; Narita et al, 1979). The other two enzyme
proteins are heterodimers resulting from the combination of a
BPGM subunit with a PGM subunit either type M or type B (Rosa
et al, 1984; Pons et al, 1985a). The BPGM homodimer is particu-
larly abundant in erythrocytes. The BPGM-type M PGM hybrid is
present in the tissues that express type M PGM subunit (skeletal
muscle and heart), and the BPGM-type B PGM hybrid is present in
the tissues that express type B PGM subunit. Moreover, in
mammalian tissues, there are two other enzyme forms that possess
only BPGP activity not stimulated by 2-phosphoglycolate (2-phos-
phoglycolate non-stimulated BPGP) and seem to be monomeric
(Carreras et al, 1981; Pons et al, 1985b).
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Table 1 Levels of PGM and BPGP activities in human lung, colon and liver normal tissues and tumours
Normal tissue Tumour
Tissue Tumour Case no. PGM BPGP PGM/BPGP PGM BPGP PGM/BPGP
Ug-' Umg-' mUg-' mUmg-, Ug-1 Umg-, mUg-1 mUmg-'
Lung Adenocarcinoma 1 1.5 0.05 600 18.5 3 4.2 0.14 340 11.0 12
2 1.8 0.06 170 5.9 11 5.4 0.19 125 3.5 43
3 2.1 0.08 495 19.4 4 4.0 0.14 220 7.5 18
4 2.7 0.08 185 5.9 15 9.1 0.29 100 3.2 91
5 3.0 0.07 150 3.5 20 7.5 0.2 80 2.5 93
6 3.8 0.1 145 4.7 26 5.1 0.16 70 1.7 72
7 5.7 0.2 190 8.1 30 10.2 0.4 125 4.9 81
Mean±s.e.m 2.9±0.5 0.09±0.01 276±71 9.4±2.5 15.6±3.9 6.5±0.9 0.2±0.03 151 ±36 4.9± 1.2 59± 12
Squamous cell
carcinoma 1 2.4 0.06 586 21.2 4 4.5 0.16 495 14.2 9
2 2.4 0.06 596 16.5 4 4.8 0.2 340 13.9 14
3 1.5 0.06 295 12.2 5 4.8 0.16 167 5.7 28
4 4.5 0.2 115 5.1 39 11.1 0.5 100 4.9 111
Mean+s.e.m. 2.7±0.6 0.09±0.03 398± 117 13±3.4 13.6±8.6 6.3± 1.6 0.2±0.08 275±88 9.6±2.5 41±23
Carcinoid 1 7.5 0.26 298 10.5 25 13.8 0.46 210 7.0 65
2 6.6 0.13 186 3.8 35 20.4 0.4 147 3.1 138
Mean ±s.e.m. 7.0±0.45 0.1 ± 0.06 112±56 7.1 ±3.3 30±5 17.1 ±3.3 0.4 ±0.03 178 ±31 5.0± 1.9 101 ±36
Colon Adenocarcinoma 1 8.8 0.22 1521 38.1 5 20.1 0.64 225 7.2 89
2 8.7 0.4 676 36.3 13 18.3 0.49 596 5.8 31
3 7.2 0.25 465 16.3 15 14.5 0.35 235 5.7 62
4 6.6 0.25 1190 44.6 5 10.8 0.33 340 10.4 32
5 6.3 0.21 676 23.6 9 15.9 0.6 615 22.2 26
6 7.5 0.2 676 18.7 11 12.6 0.26 440 9.1 28
7 7.8 0.3 1593 54.1 5 24.6 1.1 597 25.8 41
8 7.2 0.4 549 31.0 12 11.4 0.6 348 17.6 33
9 7.8 0.37 771 36.7 10 14.4 0.5 996 36.1 14
10 8.4 0.4 1047 49.8 8 12.0 0.66 897 49.0 13
Mean±s.e.m. 7.6±0.2 0.29±0.02 916± 126 35.0±4.0 9±1 15.4± 1.3 0.55±0.07 528±83 18.8±4.6 37±7
Liver Adenocarcinoma 1 6.9 0.46 215 10.0 32 8.1 0.36 170 7.6 47
2 13.5 0.29 335 7.1 40 18.0 0.47 111 5.2 162
3 15.6 0.27 200 6.0 78 20.7 0.6 175 5.5 118
4 12.0 0.31 225 5.8 53 22.2 0.6 140 3.8 158
5 15.3 0.4 200 5.3 77 19.3 0.8 110 3.0 175
6 12.0 0.33 155 4.2 76 15.9 0.6 90 3.4 176
Mean±s.e.m. 12.5±1.2 0.34±0.02 221 ±24 6.4±0.8 59±8 17.3±2.0 0.57±0.06 132±14 4.7±0.6 139±20
The activity is expressed as units per g wet tissue and as units per mg extracted protein. The comparisons for the U mg-1 of protein data are as follows: PGM activity:
normal lung vs normal liver; normal lung vs normal colon; normal liver vs normal colon, P< 0.001. Lung adenocarcinoma vs normal tissue, P< 0.01; lung squamous cell
carcinoma vs normal tissue, P < 0.04; colon adenocarcinoma vs normal tissue, P< 0.002; hepatocarcinoma vs normal tissue, P< 0.009. BPGP activity: normal colon vs
normal colon vs normal liver, P < 0.001. Lung adenocarcinoma vs normal tissue, P< 0.01; colon adenocarcinoma vs normal tissue, P< 0.002; hepatocarcinoma vs normal
tissue, P< 0.003. All other comparisons are not significant.
Enolase molecules are dimers composed of three distinct
subunits coded by separate genes and designated a (liver), i
(muscle) andy (brain) (for areview, see Day, 1982). The aa isoen-
zyme exists in most mammalian tissues. ,6 and ac enolase are
found predominantly in skeletal and heart muscle. yy and ay
enolases are present mainly in nervous tissue and in tissues with
neuroendocrine cells. They have frequently been designated as
neuron-specific enolase. The fiy hybrid has not been found, prob-
ably because the 3 and the y enolase subunits are not expressed in
the same tissue (for reviews, see Kato et al, 1983a; Taylor et al,
1983; Haimoto et al, 1985; Royds et al, 1985; Schmechel, 1985;
Marangos and Schmechel, 1987).
The present study was undertaken to determine the distribution
of total PGM, BPGP and enolase activities and isoenzymes in
lung, colon and liver carcinoma as a first step to studying the
expression ofthese isoenzymes in neoplastic cells.Only one report
has been published about PGM isoenzymes in brain tumours
(Omenn and Cheung, 1974; Omenn and Hermodson, 1975) and, to
our knowledge, no data exist on other tumours. Numerous studies
have been published on the distribution of enolase isoenzymes
in human tumours (for reviews, see Taylor et al, 1983; Royds et
al, 1985; Schmechel, 1985; Gerbitz et al, 1986; Marangos and
Schmechel, 1987; Kaiser et al, 1989). However, most data have
been obtained by immunohistochemical and immunoassay tech-
niques. To our knowledge, only two reports have been published
on the distribution of enolase isoenzyme proteins in lung tumours
(Pahlman et al, 1986; Batandier et al, 1987), and no data exist on
the distribution ofenolase isoenzymes in colon and liver tumours.
MATERIALS AND METHODS
Materials
Enzymes, substrates, cofactors and biochemicals were purchased
from either Boehringer (Mannheim, Germany) or Sigma (St Louis,
MO, USA). 3-Mercaptoethanol was from Merck (Darmstadt,
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Figure 1: Electrophoretograms of PGM isoenzymes in extracts of human normal tissues and tumours. (A) Lung: lane 1, heart extract; lanes 3 and 5,
squamous cell carcinoma; lane 7, adenocarcinoma; lanes 2, 4 and 6, normal tissues. (B) Colon: lanes 2, 4 and 6, adenocarcinoma; lanes 1, 3 and 5, normal
tissues. (C) Liver: lanes 2, 4 and 6, adenocarcinoma; lanes 1, 3 and 5, normal tissues
Table 2 PGM isoenzymes in lung, colon and liver normal tissues and tumours
Normal tissue Tumour
Tissue Tumour Case no. MM MB BB MM MB BB
Lung Adenocarcinoma 1 0 0 100 0 0 100
2 0 8 92 0 8 92
3 0 0 100 0 0 100
4 0 0 100 0 0 100
5 0 3 97 0 0 100
6 0 3 97 0 8 92
7 0 0 100 0 0 100
Squamous cell
carcinoma 1 0 4 96 0 1 99
2 0 4 96 0 0 100
3 0 4 96 0 2 98
4 0 0 100 0 0 100
Carcinoid 1 0 0 100 0 9 91
2 0 0 100 0 0 100
Colon Adenocarcinoma 1 0 0 100 0 0 100
2 0 2 98 0 0 100
3 0 0 100 1 1 99
4 0 1 99 0 0 100
5 3 6 91 0 2 98
6 3 7 90 0 3 97
7 0 6 94 0 0 100
8 0 0 100 0 0 100
9 0 4 96 0 3 97
10 0 6 94 0 3 97
Liver Adenocarcinoma 1 0 1 99 0 0 100
2 ND ND
3 0 2 98 0 1 99
4 0 3 97 0 2 98
5 0 4 96 0 2 98
6 0 3 97 0 0 100
The results are expressed as a percentage of the total activity on electrophoresis. ND, not determined.
Germany) and bovine serum albumin was from Calbiochem (La Tissue samples
Jolla, CA, USA). Other chemicals were reagent grade. Agar noble Tumour samples were obtained from surgical resection specimens:
was obtained from Difco Laboratories (Detroit,MI,USA). Cellulose seven lung adenocarcinomas, five lung squamous cell carcinomas,
acetate strips were from Helena Laboratories (Beaumont, TX, USA) two carcinoid tumours ofthe lung, ten colon adenocarcinomas and
and agarose gels were from Ciba-Coming (Palo Alto,CA,USA). six hepatocarcinomas. Samples of normal tissue were obtained
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from adjacent normal tissue that had to be removed during tumour
surgery.
Tissue extraction
Tissue extracts were prepared by homogenization in three volumes
(w/v) of cold 20 mm Tris-HCl buffer, pH 7.5, containing 1 mM
EDTA and 1 mm 3-mercaptoethanol with a Polytron homogenizer
(Luceme, Switzerland) (position 5, 20 s). Cellular debris was
removed by centrifugation at 4°C for 30 min at 12 500 g, and the
supematants were used for the assay of enzyme activities and
isoenzymes.
Enzyme and protein assays
PGM activity was measured spectrophotometrically at 300C by
coupling the formation of 2-phosphoglycerate from 3-phospho-
glycerate with the enolase, pyruvate kinase and lactate dehydroge-
nase catalysed reactions (Beutler and Stratton, 1975), as
previously described (Durany and Carreras, 1996). BPGP activity
was assayed by measuring the appearance of inorganic phosphate
from 2,3-bisphosphoglycerate (Joyce and Grisolia, 1958). The
reaction mixture was contained in a total volume of 1 ml: 50 mM
triethanolamine, pH7.6, 1 mm 2,3-bisphosphoglycerate, 2.5 mM 2-
phosphoglycolate (as activator) and the sample tested. After incu-
bation at 370C, the reaction was stopped by the addition of0.25 ml
of 25% trichloroacetic acid. After centrifugation, the inorganic
phosphate was estimated in the supematant by the method ofItaya
and Ui (1966). Enolase activity was measured spectrophotometri-
cally at 300C by coupling the formation of phosphoenolpyruvate
with the pyruvate kinase and lactate dehydrogenase catalysed
reactions (Bergmeyer, 1983), as previously described (Joseph et
al, 1996). Enzyme activities were expressed as U g-' wettissue and
as U mg-' protein (1 Unit = 1 [tmol substrate converted per min).
Protein was determined by the method of Bradford (1976), using
bovine serum albumin as a standard.
lsoenzyme analysis
The methods described previously were used to evaluate PGM
isoenzymes by cellulose acetate electrophoresis (Durany and
Carreras, 1996) and enolase isoenzymes by agarose gel elec-
trophoresis (Joseph et al, 1996).
Separation of BPGP from PGM and BPGM
PGM isoenzymes, BPGM and the BPGM-PGM hybrids were
separated from 2-phosphoglycolate non-stimulated BPGP by
highly resolutive gel filtration fast liquid chromatography (FPLC
system and Superdex 75 HR column from Pharmacia LKB
Biotechnology, Sweden). The column was equilibrated with
extraction buffer. A sample (0.2 ml) of the tissue extract was
injected, the column was eluted at a flow rate of0.1 ml min-1 and
500-[tl fractions were collected.
Statistical analysis
A one-way analysis of variance with repeated measures was
employed for statistical evaluation and used to compare enzyme
activities among different tissues. When a significant P-value was
obtained (P < 0.05), the difference between means was located
with the Tukey test (Baylar and Mosteller, 1992). To compare
PGM activity in tumour and control tissues, the Wilcoxon t-test
was used (Baylar and Mosteller, 1992). Values are reported as
means ± s.e.m. Data were analysed by InStat statistical software.
RESULTS
Distribution of PGM and BPGP activities and
isoenzymes
Table 1 summarizes the levels oftotal PGM and BPGP activities in
normal lung,colon and livertissues, and in their tumours. Figure 1
shows some ofthe PGM isoenzyme patterns determined by cellu-
lose acetate electrophoresis, and Table 2 summarizes the distribu-
tion ofPGM isoenzymes in normal and tumour tissues.
As shown, lung tissue presents a lower PGM content than liver
and colon tissues (P <0.001), which have similar PGM concentra-
tion. Normal lung, liver and colon tissues contain almost exclu-
sively BB-PGM with traces ofMB-PGM isoenzyme. Colon is the
tissue with the highest BPGP activity (P < 0.001), and no signi-
ficative difference is observedbetween the levels ofthis activity in
lung and liver. The PGM-BPGP activity ratio in colon and in lung
is not significantly different. In contrast, liver possesses a higher
PGM-BPGP activity ratio. These results indicate that lung, colon
and liver tissues differ in their PGM content and in the concentra-
tion ofsome ofthe other enzymes that also possess BPGP activity
(BPGM,BPGM-PGM hybrid and 2-phosphoglycolate non-stimu-
lated BPGP).
It has been shown that 2-phosphoglycolate non-stimulated
BPGP has a lower molecular weight than PGM, BPGM and
BPGM-PGM hybrids, and that they can be separated by gel filtra-
tion chromatography (Carreras et al, 1981; Pons et al, 1985b).
Therefore, we compared the PGM-BPGP activity ratio in liver and
lung extracts before and aftergel filtrationFPLC. It was found that
neither the enzyme activities nor the PGM-BPGP activity ratio
changed significantly after chromatography. There was correlation
between the levels of the enzyme activities in the crude extracts
and in the peaks containing the PGM, the BPGM and the
BPGM-PGM hybrid isolated by gel filtration chromatography.
The peak from liver extract was the peak with the highest PGM
activity. It was concluded that the contribution of the 2-phospho-
glycolate non-stimulated BPGP enzyme to the total BPGP activity
of the tissues is almost negligible, and that they differ in the
concentration ofPGM, BPGM and BPGM-PGM hybrid.
As summarized in Table 1, all tumours present higher PGM
activity levels than the corresponding normal tissues. However, no
changes are observed in the PGM isoenzyme patterns. As the
normal tissues, tumours contain mainly type BB-PGM, with only
traces of the MB-PGM form (Figure 1 and Table 2). In contrast to
PGM activity, the levels ofBPGP activity in all tumours are lower
than in normal tissues. Correspondingly, the PGM-BPGP activity
ratios in tumours are higher than in control tissues.
The fact that tumours present opposite changes in the levels of
PGM activity and of BPGP activity suggests that tumoral tissues
change both the concentration ofPGM and the concentration ofthe
other enzymes that also have BPGP activity. Extracts ofliver carci-
noma and of lung carcinoid were filtered through a FPLC column
in order to separate the 2-phosphoglycolate non-stimulated BPGP.
The total enzyme activities and the PGM-BPGP activity ratio of
the extracts were similar before and after chromatography. This
shows that, as in normal tissues, the contribution of 2-phosphogly-
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Table 3 Levels of enolase activity in human lung, colon, and liver normal tissues and tumours
Normal tissue Tumour
Tissue Tumour Case no. U g-1 U mg-' Ug-1 U mg-,
Lung Adenocarcinoma 1 6 0.1 17 0.3
2 5 0.07 21 0.3
3 3 0.1 20 0.5
4 2 0.08 26 0.86
5 5 0.12 17 0.47
6 7 0.15 19 0.48
7 4 0.12 11 0.28
Mean±s.e.m. 4.5± 0.6 0.10 ± 0.01 18.7 ± 1.7 0.45± 0.07
Squamous cell 1 15 0.2 23 0.2
Carcinoma 2 9 0.1 24 0.5
3 3 0.06 16 0.3
4 8 0.12 33 0.61
5 4 0.17 7 0.36
Meant ±s.e.m. 7.9 t 2.1 0.13±0.02 20.6 ± 4.3 0.39t ±0.07
Carcinoid 1 3 0.1 5 0.23
2 4 0.07 11 0.19
Mean t s.e.m. 3.5 ± 0.5 0.085 ± 0.01 8.0 ± 3.0 0.21 ± 0.02
Colon Adenocarcinoma 1 6.1 0.1 19.6 0.4
2 7.0 0.1 8.3 0.1
3 5.4 0.1 14.5 0.2
4 5.2 0.09 14.3 0.2
5 5.1 0.2 17.8 0.4
6 7.6 0.2 8.7 0.1
7 6.9 0.1 12.9 0.3
8 4.5 0.2 11.2 0.3
9 7.4 0.1 18.2 0.4
10 8.5 0.1 11.6 0.2
Mean ± s.e.m. 6.4 ± 0.4 0.13 ± 0.015 13.7 ± 1.2 0.26 ± 0.04
Liver Hepatocarcinoma 1 9 0.8 8 0.5
2 14 0.2 22 0.4
3 15 0.2 21 0.6
4 11 0.2 12 0.3
5 17 0.4 20 0.8
6 18 0.3 20 0.7
Mean ± s.e.m. 14t ±1.4 0.35t ±0.1 17.2 ± 2.3 0.56+±0.07
The activity is expressed as units per g wet tissue and as units per mg extracted protein. The comparisons for the U mg-' of protein data are as follows: normal
lung vs normal liver, P<0.001; normal colon vs normal liver, P<0.01; lung adenocarcinoma vs normal tissue, P< 0.05, colon adenocarcinoma vs normal tissue,
P< 0.05. All other comparisons are not significant.
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Figure 2 Electrophoretograms of enolase isoenzymes in extracts of human lung normal tissue and tumours. (A) Adenocarcinoma: lanes 2, 4 and 6, tumours;
lanes 3, 5 and 7, normal tissues. (B) Squamous cell carcinoma: lanes 8 and 10, tumours; lanes 9 and 11, normal tissues. (C) Carcinoid: lanes 12 and 14,
tumours; lanes 13 and 15, normal tissues. Lanes 1 and 16, human brain extracts (cortex)
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Figure 3: Electrophoretograms of enolase isoenzymes in extracts of human liver and colon normal tissues and tumours. (A) Liver: lanes 2, 4 and 6,
hepatocarcinomas; lanes 3, 5 and 7, normal tissues. (B) Colon: lanes 9, 11 and 13, adenocarcinomas; lanes 10, 12 and 14, normal tissues. Lanes 1 and 8
human brain extracts (cortex)
Table 4 Enolase isoenzymes in human lung, colon and liver normal tissues and tumours
Normal tissue Tumour
Tissue Tumour Case No. aa ayb yyC aa ay yy
Lung Adenocarcinoma 1 77 20 3 94 4 2
2 62 31 7 85 13 2
3 73 23 4 76 22 2
4 73 23 4 85 13 2
5 77 19 4 84 14 2
6 76 21 3 96 4 0
7 76 22 2 78 20 2
Mean ± s.e.m. 73.4 ± 2.0 22.7 ± 1.5 3.8 ± 0.6 85.4 ± 2.8 12.8 ± 2.6 1.7 ± 0.3
Squamous cell 1 74 22 4 84 15 1
carcinoma 2 90 10 0 92 8 0
3 81 17 2 85 13 2
4 84 14 2 70 28 2
5 78 20 2 88 12 0
Mean ± s.e.m. 81.4 ± 2.7 16.6 ± 2.1 2.0 ± 0.6 83.8 ± 3.7 15.2 ± 3.4 1.0 ± 0.4
Carcinoid 1 70 26 4 44 32 24
2 70 25 5 50 37 13
Mean±s.e.m. 70±0.0 25.5±0.5 4.5±0.5 47±3 34.5±2.5 18.5±5.5
Colon Adenocarcinoma 1 77 19 4 86 12 2
2 70 24 6 87 10 3
3 70 21 9 89 9 2
4 74 20 6 84 14 2
5 75 19 6 90 8 2
6 79 15 6 94 4 2
7 69 25 6 79 19 2
8 89 8 3 82 15 3
9 84 12 4 86 11 3
10 77 18 5 81 16 3
Mean ±s.e.m. 76.4 ± 2.0 18.1 ± 1.6 5.5 0.5 85.8 ± 1.4 11.8 ± 1.4 2.4 0.2
Liver Hepatocarcinoma 1 96 3 1 93 6 1
2 93 6 1 94 4 2
3 92 6 2 100 0 0
4 95 5 0 96 3 1
5 95 5 0 97 3 0
6 94 4 2 100 0 0
Mean ± s.e.m. 94.2 ± 0.6 4.8 ± 0.5 1.0 ± 0.3 96.7 ± 1.2 2.6 ± 0.9 0.6 ± 0.3
The results are expressed as a percentage ofthe total enolase activity on electrophoresis. The comparisons are as follows: aLung vs liver, P< 0.001; colon vs
liver, P< 0.001. bLung vs liver, P< 0.001; colon vs liver, P<0.001. cLung vs colon, P< 0.01; lung vs liver, P< 0.05; colon vs liver, P< 0.001. All other
comparisons are not significant.
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colate non-stimulated BPGP to the total BPGP activity in tumour
tissues is not relevant. In addition, these results indicate that the
decrease ofthe total BPGP activity found in tumours is caused by a
decrease ofthe BPGM and ofthe BPGM-PGM hybrid. It has to be
noted that there was a correlation between the assay of the enzyme
activities in the crude extracts and in the peaks containing the PGM,
the BPGM and the BPGM-PGM hybrid isolated by gel filtration
chromatography. Those peaks corresponding to tumour tissues had
higher PGM activity and lower BPGP activity than the peaks corre-
sponding to normal tissues.
Distribution of enolase activity and isoenzymes
Table 3 summarizes the levels of total enolase activity in normal
human lung, colon and liver tissues, and in their tumours. Figures
2 and 3 show the electrophoretograms of some tumours deter-
mined by agarose gel electrophoresis, and Table 4 summarizes the
data obtained.
As shown, liver tissue possesses a higherenolase content than lung
(P < 0.001) and colon (P < 0.01) tissues, which have similar enolase
concentration. All tumours have higher enolase activity than the
corresponding normal tissues, although only in lung and colon
adenocarcinoma are the differences observed statistically significant.
The normal tissues possess all the three enolase isoenzymes,
although the proportion of aa-enolase is much larger than the
proportions of ay-and yy-enolase. Normal lung and colon tissues
present enolase isoenzymes in similar proportions. Liver tissue has
lower proportions of enolase isoenzymes containing the y subunit
(ay- andyy-enolase). Five ofseven lung adenocarcinomas and four
offive squamous cell carcinomas ofthe lung show a lower content
of ay- and yy-enolase than the corresponding normal tissue. In
contrast, one squamous cell carcinoma and two carcinoid tumours
of the lung present higher proportions of the enolase isoenzymes
containing the y subunit than the normal tissues. Colon and liver
carcinomas have lower proportions of ay- and yy-enolase than
normal tissues, although in hepatocarcinomas the decrease in the
proportion of the enolase isoenzymes containing the y subunit is
less evident than in colon adenocarcinomas.
DISCUSSION
Our results show that, in normal human lung, colon and liver
tissue, the PGM and the enolase activities are much higher than the
BPGP activity, which is in agreement with the different functions
of these enzymes. PGM and enolase are enzymes of the main
glycolytic pathway, whereas the BPGP activity participates in the
2,3-bisphosphoglycerate bypass (or Rapoport-Luebering shunt), a
collateral deviation ofglycolysis (Rapoport, 1968).
The data presented on the distribution of PGM isoenzymes in
normal human lung, colon and liver agree with preliminary results
(Durany and Carreras, 1996) and confirm that in all these tissues
type BB-PGM is the predominant PGM isoenzyme. They contain
traces of MB-PGM and no detectable MM-PGM. Our results also
show that in these tissues most ofthe total BPGP activity is caused
by PGM, BPGM and BPGM-PGM hybrid. The contribution of 2-
phosphoglycolate non-stimulated BPGP is very low. Similar
results were obtained in other tissues ofpig and cat (Carreras et al,
1981; Pons et al, 1985b).
Our data on the distribution ofenolase isoenzymes in tissues are
in agreement with the results of others. It has been shown by
immunoassay that the three enolase subunits are present in normal
human lung, colon and liver, although the proportion of a subunit
is much larger than the proportions of 3 andy subunits (Schmechel
et al, 1978; Marangos et al, 1979, 1980; Kato et al, 1983a, b;
Taylor et al, 1983; Fujita et al, 1987; Marangos and Schmechel,
1987). Hullin et al (1980) found that yy-enolase determined by ion-
exchange chromatography represented 0.7%, 1.3% and 0.04% of
the total enolase activity in extracts of lung, large intestine and
liver respectively. Batandier et al (1987) showed by elec-
trophoretic analysis that aa-enolase was the predominant isoen-
zyme in human lung. ay-Enolase represented a low proportion
(5.75 + 0.25%) ofthe total enolase activity and yy-enolase was not
detectable. The results presented here confirm that the y-enolase
subunit is expressed in normal lung, colon and liver, and show
that, in lung and in colon tissues, ay-enolase represents an appre-
ciable proportion (21 ± 5.1% and 18.1 ± 1.6% respectively) ofthe
total enolase activity. In liver, the proportion of ay-enolase is
lower (4.8 ± 0.5%) than in the two other tissues.
In all lung, colon and liver tumours, we found an increase in
PGM and enolase activities and a decrease in 2-phosphoglycolate-
stimulated BPGP activity. In contrast, in brain tumours a decrease
of the enolase and PGM activities was observed (Joseph et al,
1996; N Durany and J Carreras, unpublished results).
In the tumours studied, we have not detected changes in the
distribution of PGM isoenzymes, but we have observed some
alterations in the enolase isoenzyme patterns. In colon and liver
carcinomas, and in most adenocarcinomas and squamous cell
carcinomas ofthe lung, we found adecrease in enolase isoenzymes
containing type y subunit (ay- and yy-enolase). In contrast, in two
carcinoid tumours and in one squamous cell carcinoma ofthe lung,
we observed an increase in these enolase isoenzymes. In addition,
we have deduced that the decrease ofthe 2-phosphoglycolate-stim-
ulated BPGP activity observed in all tumours reflects a decrease of
the BPGM and the BPGM-PGM hybrid enzyme levels.
Our results on enolase isoenzymes in tumours can be compared
with data from other authors but, to our knowledge, no previous
data exist on PGM isoenzymes in lung, colon and liver tumours.
By enzyme immunoassay, it has been shown that the a-enolase
subunit is abundant and that theP-enolase subunit is present at low
levels in most lung tumours (Nakajima et al, 1985; Fujita et al,
1987). The presence of the y-enolase subunit in lung neuroen-
docrine tumours has been well documented by immunohistochem-
istry, but its presence in non-neuroendocrine tumours is
controversial (for reviews, see Marangos and Schmechel, 1987;
Kaiseret al, 1989). Pahlman et al (1986) found using ion-exchange
chromatography that non-small-cell carcinoma cell lines had
measurable quantities of neuron-specific enolase, although its
levels were 10- to 100-fold lower than those found in small-cell
carcinoma cell lines. Batandier et al (1987) found by elec-
trophoresis ay-enolase in significantly higher proportion in lung
neuroendocrine carcinomas than in non-neuroendocrine tumours.
yy-Enolase was present at high levels in lung neuroendocrine
carcinomas and consistently absent in non-neuroendocrine
tumours. In disagreement with these authors, we have detected yy-
enolase in non-neuroendocrine lung tumours, although at lower
levels than in normal lung tissues and lung carcinoids. The
discrepancy is probably owing to a higher sensitivity of the
method ofdetection used by us.
By immunoassay, the y-enolase subunit was detected in gastric
and gut carcinoids (Tapia et al, 1981; Simpson et al, 1984; Nash et
al, 1986), and in a cell line from a neuroendocrine tumour ofcolon
(Reeve et al, 1986). In contrast, no y-enolase staining was found in
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colon adenocarcinomas (Simpson et al, 1984; Vinores et al, 1984;
Fukuda et al, 1989), and low levels ofreactivity were detected in a
cell line from a colon carcinoma (Reeve et al, 1986). As indicated
above, we have detected ay- and yy-enolase in colon adenocarci-
nomas, although at a lower proportion than in normal tissue.
By immunohistochemistry, y-enolase was found to be negative
in hepatocellular carcinoma (Vinores et al, 1984; Fujita et al,
1987), although it was present in one oftwo cases offibrolamellar
carcinoma with neurosecretory granules (Fujita et al, 1987). Our
results indicate that, although at a very low proportion, ay- andy-
enolase isoenzymes can be detected in liver carcinomas.
In conclusion, we have found that in hepatocarcinoma, colon
and lung adenocarcinoma, lung squamous cell carcinoma and
carcinoid tumourofthe lung,theexpression ofPGM subunits does
not suffer any qualitative change. In tumour tissues, the total PGM
activity increases but the relative expression oftype B and type M
PGM subunits does not vary. As in the normal tissues, type B
subunit is predominant. The total enolase activity also increases in
all tumours studied by us but, in contrast to PGM, the distribution
ofenolase isoenzymes in tumour tissues presents some alterations.
In two carcinoid tumours and in one squamous cell carcinoma of
the lung, the proportion of enolase isoenzymes containing type y
subunit was found to be increased. In all other tumours, it was
found to be decreased. The changes in the proportions of enolase
isoenzymes in tumours could reflect achange in the proportions of
the different cell types present in the tissues. But a change in the
expression of a- and y-enolase subunits cannot be excluded, since
it has been shown that cells undergoing mitosis activate the
expression of the a-enolase subunit. It has been reported that a-
enolase is expressed at relatively high levels in all actively prolif-
erating human cell lines but at very low levels in normal resting
peripheral blood lymphocytes, in which its synthesis is induced
upon mitogenic stimulation (Giallongo et al, 1986a, b). Moreover,
it has been shown that expression of the genes encoding four
glycolytic enzymes, including enolase, is specifically stimulated in
quiescent rat fibroblast by eitherepidermal growth factor or serum
(Matrisian et al, 1985).
From the diagnostic point of view, we conclude that PGM and
enolase isoenzymes are not good markers for the tumours studied
by us. Only in carcinoid tumours of the lung can the increase in
neuron-specific enolase have clinical applications, as already indi-
cated by others (Royds et al, 1985; Schemechel, 1985; Gerbitz et
al, 1986; Marangos-and Schmechel, 1987; Kaiser et al, 1989).
ABBREVIATIONS
BPGM, 2,3-bisphosphoglycerate mutase; BPGP, 2,3-bisphospho-
glycerate phosphatase; PGM, phosphoglycerate mutase.
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